Amgen's experimental obesity drug, MariTide, shows promising...
Amgen's experimental obesity drug, MariTide, shows promising early results with patients losing up to 14.5% of their body weight. The less-frequent dosing could offer more convenience and less manufacturing burden.
Amgen's Quarterly Results Top Expectations Despite Enbrel Sales Decline
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3221Followers
0Following
7986Visitors
Follow